Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Neurocrine Biosciences, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Neurocrine Biosciences, Inc. - Product Pipeline Review - 2014', provides an overview of the Neurocrine Biosciences, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Neurocrine Biosciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Neurocrine Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Neurocrine Biosciences, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Neurocrine Biosciences, Inc.'s pipeline products Reasons to buy - Evaluate Neurocrine Biosciences, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Neurocrine Biosciences, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Neurocrine Biosciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Neurocrine Biosciences, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurocrine Biosciences, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Neurocrine Biosciences, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Neurocrine Biosciences, Inc. Snapshot 5 Neurocrine Biosciences, Inc. Overview 5 Key Information 5 Key Facts 5 Neurocrine Biosciences, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Neurocrine Biosciences, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Neurocrine Biosciences, Inc. - Pipeline Products Glance 13 Neurocrine Biosciences, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Neurocrine Biosciences, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Neurocrine Biosciences, Inc. - Drug Profiles 15 NBI-69734 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 valbenazine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 verucerfont 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Drug to Inhibit VMAT-2 for Schizophrenia and Movement Disorder 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 G Protein-Coupled Receptor 119 Agonist 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GnRH Antagonists 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GPCR Antagonist 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules for CNS Disorders 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Neurocrine Biosciences, Inc. - Pipeline Analysis 26 Neurocrine Biosciences, Inc. - Pipeline Products by Target 26 Neurocrine Biosciences, Inc. - Pipeline Products by Route of Administration 27 Neurocrine Biosciences, Inc. - Pipeline Products by Molecule Type 28 Neurocrine Biosciences, Inc. - Pipeline Products by Mechanism of Action 29 Neurocrine Biosciences, Inc. - Recent Pipeline Updates 31 Neurocrine Biosciences, Inc. - Dormant Projects 35 Neurocrine Biosciences, Inc. - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 tiplimotide 37 indiplon 37 prasterone 37 Neurocrine Biosciences, Inc. - Company Statement 38 Neurocrine Biosciences, Inc. - Locations And Subsidiaries 43 Head Office 43 Other Locations & Subsidiaries 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Neurocrine Biosciences, Inc., Key Information 5 Neurocrine Biosciences, Inc., Key Facts 5 Neurocrine Biosciences, Inc. - Pipeline by Indication, 2014 8 Neurocrine Biosciences, Inc. - Pipeline by Stage of Development, 2014 9 Neurocrine Biosciences, Inc. - Monotherapy Products in Pipeline, 2014 10 Neurocrine Biosciences, Inc. - Out-Licensed Products in Pipeline, 2014 11 Neurocrine Biosciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Neurocrine Biosciences, Inc. - Phase II, 2014 13 Neurocrine Biosciences, Inc. - Preclinical, 2014 14 Neurocrine Biosciences, Inc. - Pipeline by Target, 2014 26 Neurocrine Biosciences, Inc. - Pipeline by Route of Administration, 2014 27 Neurocrine Biosciences, Inc. - Pipeline by Molecule Type, 2014 28 Neurocrine Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2014 30 Neurocrine Biosciences, Inc. - Recent Pipeline Updates, 2014 31 Neurocrine Biosciences, Inc. - Dormant Developmental Projects,2014 35 Neurocrine Biosciences, Inc. - Discontinued Pipeline Products, 2014 37 Neurocrine Biosciences, Inc., Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.